Although Tfh differentiation may divert T cells from more efficient (e.g., IFNγ-producing) anti-tumor differentiation, it provides support for the tantalizing possibility that tumor-elicited B cell responses could be exploited against cancer (Carmi et al., 2015). The gene discussed is IFNG; the disease is cancer.